Independent AI index
for professionals

Home / Safety / Kimi for pharmaceutical industry

Moonshot AI

How safe is Kimi for the pharmaceutical industry?

GDPR profileOur summary of what the provider itself publishes about your data: EU hosting possible, no training on your data for business use, and self-hostable. Caution is given to a model with a documented issue, such as an investigation by a regulator. How we measure for the pharmaceutical industryCaution

Kimi has a concrete GDPR concern. The parent company is based in Beijing and falls under Chinese security legislation; the privacy policy does not explicitly name that jurisdiction. No confidential data in the consumer app; self-hosting the open weights is the safe route. Weigh this heavily before using it in the pharmaceutical industry.

Where does Kimi stand in pharmaceutical industry?

Shared spot 19 of 25 options for the pharmaceutical industry (professional tools and general assistants) on GDPR profile. 7 options, like Kimi, have a profile to watch. Each tile is an option we track for this field; click for the check.

Strong5
Good3
Limited7
Unknown3
Caution7

Published safeguards

–EU hosting possibleNot known
–No training on your data (business)Not known
✓Self-hostable (on-premise)Yes

The international service is provided by Moonshot AI Pte. Ltd. (Singapore); according to the privacy policy, data is stored on servers in Singapore and content may be used to improve the service. The K2 models are open-weight and can be self-hosted.

How to use Kimi safely

  • Use the business variant and sign a data processing agreement (DPA).
  • Do not enter unnecessary personal data into prompts; anonymise where possible.
  • Ask the provider explicitly where data is stored and processed.
  • Keep a professional in the loop: in this sector it concerns health data of trial participants and patients (special category personal data under art.

Stronger or equally strong in the pharmaceutical industry

CradleCradle (Amsterdam, the Netherlands and Zürich, Switzerland)CastorCastor (Amsterdam, Netherlands)BiolevateBiolevate (Paris, France)Aily LabsAily Labs GmbH (Munich, Germany)ClaudeAnthropic

Latest developments

26 July 2026Kimi K3 open weights (27 July): self-hosting avoids China transfer, licence still unclear

On 27 July 2026, Moonshot AI published the full open weights of Kimi K3 (2.8 trillion parameters, 1M-token context) on Hugging Face. Self-hosting on EU infrastructure sidesteps the GDPR data transfer problem of the hosted API (servers in China, no SCCs published). Point of attention: the final licence terms were not yet published at launch (26 July), Kimi K2 carried commercial restrictions above a certain usage scale. Verify the licence before production use. Infrastructure requirement: approx. 1.4 TB of storage, 350–400 GB of GPU memory with MXFP4 quantisation. source

16 July 2026Kimi K3: no opt-out for model training, data processed in China

At the launch of Kimi K3 (16 July 2026), Moonshot AI's privacy policy states that user content may be used for model training and optimisation, with no in-product opt-out. API calls via platform.moonshot.ai are processed on servers in China; an adequacy decision or SCCs are not explicitly documented. For EU organisations: do not enter personal data until Moonshot publishes a GDPR-compliant set-up. Self-hosting on EU infrastructure (open weights available from around 27 July 2026) avoids the transfer problem. source

Questions

How safe is Kimi for the pharmaceutical industry?
Kimi has a concrete GDPR concern. The parent company is based in Beijing and falls under Chinese security law; the privacy policy does not explicitly name that jurisdiction. Keep confidential data out of the consumer app; self-hosting the open weights is the safe route. Weigh this heavily before you deploy it in the pharmaceutical industry. There is a concrete GDPR concern, read the details on the page.
Does Kimi train on my data?
The international service is provided by Moonshot AI Pte. Ltd. (Singapore); according to the privacy policy, data is stored on servers in Singapore and content may be used to improve the service. The K2 models are open-weight and can be self-hosted.
What should I look out for with AI in the pharmaceutical industry?
This sector involves health data of trial participants and patients (special category personal data under Article 9 GDPR) and confidential research data. Ask every provider where the data is stored and whether it is used to train models: Castor hosts in the Netherlands (Google Cloud europe-west4) and does not share data or models between customers, Cradle states that source data never goes to third-party AI models, Iris.ai hosts on AWS in Ireland and Germany. Biolevate and Ennov also run in private cloud or on-premises. With Veeva Vault AI and Yseop, texts go to Anthropic models via Amazon Bedrock; check the region and the data processing agreement. If you work in GxP processes, an AI tool must also be validated (EU GMP Annex 11) and a competent employee remains responsible. For AI in medicines development, the EMA has a reflection paper (2024) and is working with the FDA on joint principles.

Source documents

platform.kimi.aikimik2ai.comhuggingface.co

Everything about Kimi Best AI for the pharmaceutical industry

Summarised by the editorial team from provider documentation · not legal advice

Last checked: 1 November 2026 · How we check

Next stepAll 25 options for pharmaceutical industryProfessional tools and general assistants side by side, on GDPR profile, price and quality.

Every Friday: what changed in AI for the pharmaceutical industry

New models, prices, oversight and tools, with sources and what it means for you. One email a week, unsubscribe with one click.

View a sample

We only use your address for this newsletter. You confirm first by email.